Forte Biosciences Secures $53 Million in Oversubscribed Financing
Deal News | Nov 20, 2024 | Paul Hastings
Paul Hastings LLP has played an instrumental advisory role for TD Securities (USA) LLC in Forte Biosciences, Inc.'s oversubscribed $53 million PIPE (Private Investment in Public Equity) financing round. Forte Biosciences, a biotech company listed on NASDAQ under the ticker FBRX, has successfully attracted significant investment interest, culminating in a substantial capital raise. The prominent law firm mobilized a specialized team led by Seo Salimi, the Co-head of Equity Capital Markets, and Will Magioncalda, a partner at the firm, to ensure efficient and successful transaction execution. Paul Hastings brings to the table a breadth of expertise in finance and corporate law, widely recognized across various sectors including mergers & acquisitions, private equity, and corporate finance. This move strengthens Forte Biosciences' financial position, enhancing its capability to pursue strategic ventures and growth opportunities in the life sciences arena.
Sectors
- Investment Banking
- Legal Services
- Biotechnology
- Equity Capital Markets
Geography
- United States – The transaction involves U.S.-based entities such as TD Securities (USA) LLC, and Forte Biosciences is also a U.S.-listed company.
Industry
- Investment Banking – TD Securities is involved as the lead placement agent in the private placement deal, indicating significant activity within the investment banking sector.
- Legal Services – Paul Hastings provides crucial legal guidance and advisory services in the transaction, highlighting the role of legal firms in facilitating investment activities.
- Biotechnology – Forte Biosciences operates within the biotech sector, which is the focus of the PIPE financing deal.
- Equity Capital Markets – The deal involves equity capital markets, as it pertains to public equity financing through a PIPE transaction.
Financials
- 53 million USD – The total value of the oversubscribed PIPE financing secured by Forte Biosciences.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Paul Hastings LLP | Legal Advisor | Company | Paul Hastings is the law firm advising TD Securities in the private placement transaction. |
| TD Securities (USA) LLC | Lead Placement Agent | Company | TD Securities acted as the lead placement agent for the PIPE financing round. |
| Forte Biosciences, Inc. | Target Company | Company | Forte Biosciences is the biotechnology company receiving the $53 million funding. |
| Seo Salimi | Co-head of Equity Capital Markets, Paul Hastings | Person | Seo Salimi led the advisory team at Paul Hastings for this transaction. |
| Will Magioncalda | Partner, Paul Hastings | Person | Will Magioncalda was a key partner at Paul Hastings involved in the advisory for the transaction. |